Evidence map›Paper›PMID 32456181›Full record

ArticleCancers2020

Can

Christos Sachpekidis, Annette Kopp-Schneider, Maximilian Merz, Anna Jauch, Marc-Steffen Raab, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Prognostic significance ofAmerican journal of nuclear medicine and molecular imaging · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Christos SachpekidisClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 69120 Heidelberg, Germany.
Annette Kopp-SchneiderDepartment of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Maximilian MerzDepartment of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
Anna JauchInstitute for Human Genetics, University of Heidelberg, 69120 Heidelberg, Germany.
Marc-Steffen RaabDepartment of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
Hartmut GoldschmidtDepartment of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
Antonia Dimitrakopoulou-StraussClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 69120 Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an unmet need for positron emission tomography (PET) radiotracers that can image bone disease in multiple myeloma (MM) in a more sensitive and specific way than the widely used

Indexed as

dynamic 18F-NaF PET/CTmultiple myelomaprogression-free survival (PFS)standardized uptake value (SUV)two-tissue compartment model

Identifiers

PMID32456181
PMCPMC7281312
OpenAlexW3028267696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.